Status:
WITHDRAWN
Protection of Ovarian Function With Goserelin Acetate in Premenopausal Early Breast Cancer Patients With Chemotherapy
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Ovarian Function
Eligibility:
FEMALE
18-45 years
Phase:
PHASE3
Brief Summary
Primary objective of this study is to determine the effectiveness of goserelin acetate (Zoladex) in preserving ovarian function in premenopausal women undergoing adjuvant chemotherapy for primary inva...
Eligibility Criteria
Inclusion
- Pathologically confirmed invasive breast carcinoma
- Candidates for adjuvant chemotherapy for primary breast cancer
- Premenopausal, verified before chemotherapy is begun as satisfying both cyclic vaginal bleeding and appropriate hormone levels
Exclusion
- Previous systemic chemotherapy
- Pregnancy
- Stage IV breast cancer
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2012
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT00888082
End Date
April 1 2012
Last Update
December 10 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ankara, Turkey (Türkiye)
2
Research Site
Istanbul, Turkey (Türkiye)
3
Research Site
Kayseri, Turkey (Türkiye)